Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05530421 · ClinicalTrials.gov registry record · Phase 2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
A Phase 2 study of Relapsed and Refractory Multiple Myeloma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT05530421 is a Phase 2 study of Relapsed and Refractory Multiple Myeloma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 33 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT05530421, a Phase 2 study of Relapsed and Refractory Multiple Myeloma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Selinexor
- DRUG Dexamethasone
Study Locations (3)
Florida
- University of Miami, Lennar Foundation Medical Center - Coral Gables
- University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- University of Miami, Sylvester Comprehensive Cancer Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-03-26 |
| Est. Completion | 2030-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05530421
The ClinicalTrials.gov registry entry for NCT05530421 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed and Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT05530421 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05530421 about?
NCT05530421 is a clinical study titled "Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma". The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
What is the current status of trial NCT05530421?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-03-26. Estimated completion is 2030-03-26.
What conditions does trial NCT05530421 study?
This clinical trial studies the following conditions: Relapsed and Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05530421?
The interventions under investigation include: Venetoclax (DRUG), Selinexor (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05530421?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05530421 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed and Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.